The incorporation of radiation therapy alongside the inhibition of the PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) pathways exhibited certain efficacy in patients with resistant CRC, who have historically shown limited response to simultaneous PD-1 and CTLA4 pathway inhibition [76]. The gene discussed is CTLA4; the disease is colorectal carcinoma.